Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medrx CoTSE:4586 +3.64%57 EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus rates TSE:4586 with a GF Score™ of 57/100 and a GF Value™ of 円70.55 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 961 Drug Manufacturers companies, Medrx Co ranks worse than 97.4% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Medrx Co's EBITDA for the
three
months ended in Dec. 2025 was 円0.00 Mil. Medrx Co's Revenue for the
three
months ended in Dec. 2025 was 円0.00 Mil. Therefore, Medrx Co's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.
Medrx Co (TSE:4586) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Medrx Co EBITDA Margin % Related Terms
Medrx Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Medrx Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Medrx Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medrx Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medrx Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Medrx Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medrx Co (TSE:4586) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medrx Co and its competitors. According to the industry distribution chart, Medrx Co ranks #936 out of 961 companies in the Drug Manufacturers industry, placing it in the top 97.4%.
Is Medrx Co's EBITDA Margin % too high?
Medrx Co's current EBITDA Margin % is 0.00%. Based on the distribution chart, Medrx Co ranks #936 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medrx Co has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medrx Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medrx Co ranks #936 out of 961 companies for EBITDA Margin %. This places Medrx Co in the lower half of its industry. The industry median EBITDA Margin % is 12.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medrx Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medrx Co's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medrx Co stock overvalued right now?
Based on GuruFocus' analysis, Medrx Co (TSE:4586) is currently considered Modestly Undervalued. The stock's GF Value™ is 円70.55, compared to a current price of 円57.00 — trading 19.2% below its estimated fair value. The current EBITDA Margin % is 0.00%. Medrx Co's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Medrx Co (TSE:4586), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medrx Co (TSE:4586) Overvalued in 2026?
Based on GuruFocus' analysis, Medrx Co stock appears to be undervalued.
The current stock price of 円57.00 is trading 19.2% below its estimated GF Value™ of 円70.55.
GuruFocus considers Medrx Co to be Modestly Undervalued.
Key valuation signals for TSE:4586:
EBITDA Margin %: 0.00%
GF Value™: 円70.55 vs. price of 円57.00 (19.2% below fair value)
No single metric tells the full story. See the TSE:4586 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medrx Co Ltd is a pharmaceutical drug development company founded in January, 2002. The Company engaged in the research and development of pharmaceutical products utilizing the pharmaceutical formulation technology based on ionic liquid transdermal system. The Company develops new pharmaceutical candidates and licenses other companies to produce the pharmaceuticals after clinical trials. Its main products include analgesic patches for anti-inflammatory and pain relief.
57GF Score
Get the complete analysis for TSE:4586
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4586 has been successfully added to your 
